Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection

Habiba Hassouna¹, Abhishek Deshpande^{1

2}

Affiliations

¹ Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
² Medicine Institute Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA.

Comment

Habiba Hassouna et al. Evid Based Med. 2017 Aug.

. 2017 Aug;22(4):150-151.

doi: 10.1136/ebmed-2017-110722. Epub 2017 Jul 17.

Habiba Hassouna¹, Abhishek Deshpande^{1

2}

¹ Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
² Medicine Institute Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA.

No abstract available

Conflict of interest statement

Competing interests: AD has received research funding from Clorox, 3M and Steris.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Wilcox MH, et al. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615. N Engl J Med. 2017. PMID: 28121498 Clinical Trial.